中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

精准医学时代下肝内胆管癌的发病机制与临床转化

尤文化 梁渊 吕凌

引用本文:
Citation:

精准医学时代下肝内胆管癌的发病机制与临床转化

DOI: 10.3969/j.issn.1001-5256.2021.04.045
基金项目: 

国家自然科学基金 (81522020)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:尤文化负责文献检索,阅读及综述撰写;梁渊负责文献检索及分析汇总;吕凌负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    作者简介:

    尤文化(1996—),男,主要从事肝胆肿瘤的生物信息学与转化医学研究

    通信作者:

    吕凌,lvling@njmu.edu.cn

  • 中图分类号: R735.8

Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine

  • 摘要:

    肝内胆管癌(ICC)是仅次于肝细胞癌的第二大肝脏恶性肿瘤,占所有原发性肝癌的15%~20%。近年来,全球ICC的发病率呈上升趋势。但因其起病隐匿,恶性程度高,侵袭能力强,多数患者就诊时就已处于终末期,失去了手术的最佳时机。随着二代测序技术的不断发展,使得ICC治疗不断向个体化、精准化方向发展。介绍了ICC在发病机制、分子分型、早期诊断方面等基础研究的进展,并回顾了近几年ICC的临床转化研究。希望通过其进展,为ICC的治疗和临床研究提供新思路。

     

  • 表  1  ICC液体活检标志物

    标志物 检测样本 特异度 敏感度 结论
    CNV[29] 胆汁 98.9% 75.0% 高准确度
    CRP等[30] 血清外泌体 - - 显著高于癌前病变
    CTC[31] 外周血 - - 与预后相关
      注:-,原文未提及;CNV,拷贝数变异;CTC,循环肿瘤细胞。
    下载: 导出CSV
  • [1] KHAN SA, THOMAS HC, DAVIDSON BR, et al. Cholangiocarcinoma[J]. Lancet, 2005, 366(9493): 1303-1314. DOI: 10.1016/S0140-6736(05)67530-7
    [2] BRIDGEWATER J, GALLE PR, KHAN SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6): 1268-1289. DOI: 10.1016/j.jhep.2014.01.021
    [3] SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S. : Intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5): 594-599. DOI: 10.1634/theoncologist.2015-0446
    [4] LIU ZH, CHEN Z, MA LL, et al. Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma[J]. Acta Gastroenterol Belg, 2012, 75(2): 215-218. http://www.ncbi.nlm.nih.gov/pubmed/21431970
    [5] YOH T, HATANO E, SEO S, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: The impact and selection of repeat surgery[J]. World J Surg, 2018, 42(6): 1848-1856. DOI: 10.1007/s00268-017-4387-7
    [6] HWANG S, LEE YJ, SONG GW, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: A single-center experience of 659 cases[J]. J Gastrointest Surg, 2015, 19(7): 1291-1304. DOI: 10.1007/s11605-015-2803-6
    [7] MOEINI A, SIA D, BARDEESY N, et al. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma[J]. Clin Cancer Res, 2016, 22(2): 291-300. DOI: 10.1158/1078-0432.CCR-14-3296
    [8] FAN B, MALATO Y, CALVISI DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice[J]. J Clin Invest, 2012, 122(8): 2911-2915. DOI: 10.1172/JCI63212
    [9] SEKIYA S, SUZUKI A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes[J]. J Clin Invest, 2012, 122(11): 3914-3918. DOI: 10.1172/JCI63065
    [10] GUEST RV, BOULTER L, KENDALL TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma[J]. Cancer Res, 2014, 74(4): 1005-1010. DOI: 10.1158/0008-5472.CAN-13-1911
    [11] NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375
    [12] FARSHIDFAR F, ZHENG S, GINGRAS MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles[J]. Cell Rep, 2017, 18(11): 2780-2794. DOI: 10.1016/j.celrep.2017.02.033
    [13] WANG L, ZHU H, ZHAO Y, et al. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience[J]. J Transl Med, 2020, 18(1): 273. DOI: 10.1186/s12967-020-02437-2
    [14] ANDERSEN JB, THORGEIRSSON SS. Genetic profiling of intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2012, 28(3): 266-272. DOI: 10.1097/MOG.0b013e3283523c7e
    [15] MENG F, WEHBE H, HENSON R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes[J]. Oncogene, 2008, 27(3): 378-386. DOI: 10.1038/sj.onc.1210648
    [16] PLIESKATT J, RINALDI G, FENG Y, et al. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma[J]. BMC Cancer, 2015, 15: 309. DOI: 10.1186/s12885-015-1270-5
    [17] MENG F, HENSON R, LANG M. et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines[J]. Gastroenterology, 2006, 130(7): 2113-2129. DOI: 10.1053/j.gastro.2006.02.057
    [18] ZHANG M, YANG H, WAN L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(5): 1118-1130. DOI: 10.1016/j.jhep.2020.05.039
    [19] MCNAMARA MG, TEMPLETON AJ, MAGANTI M, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer[J]. Eur J Cancer, 2014, 50(9): 1581-1589. DOI: 10.1016/j.ejca.2014.02.015
    [20] ZHOU SL, DAI Z, ZHOU ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils[J]. Carcinogenesis, 2014, 35(3): 597-605. DOI: 10.1093/carcin/bgt397
    [21] SUBIMERB C, PINLAOR S, KHUNTIKEO N, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma[J]. Mol Med Rep, 2010, 3(4): 597-605. http://www.ncbi.nlm.nih.gov/pubmed/21472285
    [22] BOULTER L, GUEST RV, KENDALL TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited[J]. J Clin Invest, 2015, 125(3): 1269-1285. DOI: 10.1172/JCI76452
    [23] VIVIER E, UGOLINI S, BLAISE D, et al. Targeting natural killer cells and natural killer T cells in cancer[J]. Nat Rev Immunol, 2012, 12(4): 239-252. DOI: 10.1038/nri3174
    [24] SEEHAWER M, HEINZMANN F, D'ARTISTA L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer[J]. Nature, 2018, 562(7725): 69-75. DOI: 10.1038/s41586-018-0519-y
    [25] JOB S, RAPOUD D, DOS SANTOS A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3): 965-981. DOI: 10.1002/hep.31092
    [26] CHAISAINGMONGKOL J, BUDHU A, DANG H, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma[J]. Cancer Cell, 2017, 32(1): 57-70.e3. DOI: 10.1016/j.ccell.2017.05.009
    [27] SIA D, HOSHIDA Y, VILLANUEVA A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840. DOI: 10.1053/j.gastro.2013.01.001
    [28] XU RH, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. DOI: 10.1038/nmat4997
    [29] SHEN N, ZHANG D, YIN L, et al. Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer[J]. Oncol Rep, 2019, 42(2): 549-560. http://www.researchgate.net/publication/333518985_Bile_cell-free_DNA_as_a_novel_and_powerful_liquid_biopsy_for_detecting_somatic_variants_in_biliary_tract_cancer
    [30] ARBELAIZ A, AZKARGORTA M, KRAWCZYK M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2017, 66(4): 1125-1143. DOI: 10.1002/hep.29291
    [31] YANG JD, CAMPION MB, LIU MC, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma[J]. Hepatology, 2016, 63(1): 148-158. DOI: 10.1002/hep.27944
    [32] LAMARCA A, PALMER DH, WASAN HS, et al. ABC-06 | A randomised phase Ⅲ, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy[J]. J Clin Oncol, 2019, 37(15 Suppl): 4003.
    [33] BEKAⅡ-SAAB TS, VALLE JW, CUTSEM EV, et al. FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements[J]. Future Oncol, 2020, 16(30): 2385-2399. DOI: 10.2217/fon-2020-0429
    [34] ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1
    [35] ABOU-ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807. DOI: 10.1016/S1470-2045(20)30157-1
    [36] BANG YJ, UENO M, MALKA D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies[J]. J Clin Oncol, 2019, 37(15_Suppl): 4079. DOI: 10.1200/JCO.2019.37.15_suppl.4079
    [37] LIN J, SHI W, ZHAO S, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with next-generation sequencing[J]. J Clin Oncol, 2018, 36(4 Suppl): 500. http://www.researchgate.net/publication/330096463_Lenvatinib_plus_checkpoint_inhibitors_in_patients_pts_with_advanced_intrahepatic_cholangiocarcinoma_ICC_Preliminary_data_and_correlation_with_next-generation_sequencing
    [38] CHEN WX, LI GX, HU ZN, et al. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review[J]. Medicine (Baltimore), 2019, 98(45): e17832. DOI: 10.1097/MD.0000000000017832
    [39] QIN S, CHEN Z, LIU Y, et al. A phase Ⅱ study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019, 37(15 Suppl): 4074. http://www.researchgate.net/publication/333406920_A_phase_II_study_of_anti-PD-1_antibody_camrelizumab_plus_FOLFOX4_or_GEMOX_systemic_chemotherapy_as_first-line_therapy_for_advanced_hepatocellular_carcinoma_or_biliary_tract_cancer
    [40] OH D, LEE K, LEE D, et al. Phase Ⅱ study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ±tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC)[J]. J Clin Oncol, 2020, 38(15 Suppl): 4520. http://www.researchgate.net/publication/341632436_Phase_II_study_assessing_tolerability_efficacy_and_biomarkers_for_durvalumab_D_tremelimumab_T_and_gemcitabinecisplatin_GemCis_in_chemo-naive_advanced_biliary_tract_cancer_aBTC
    [41] SAHAI V, GRIFFITH K A, BEG M S, et al. A multicenter randomized phase Ⅱ study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)[J]. J Clin Oncol, 2020, 38(15 Suppl): 4582.
  • 加载中
表(1)
计量
  • 文章访问数:  624
  • HTML全文浏览量:  244
  • PDF下载量:  83
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-16
  • 录用日期:  2020-10-16
  • 出版日期:  2021-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回